Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 17 March 2017

Indication(s)

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cushing's Syndrome

Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?

Visit Cushing's Syndrome

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 1 more

Visit Prostate Cancer

Related Content

More information

Category Value
Agency product number EMEA/H/C/001160
Orphan designation No
Date First Approved 04-11-2009
Type POM
Marketing authorisation holder Novartis Europharm Ltd.